Brind.

Analyst Reports Compare Financial Performance of Relay Therapeutics and I-Mab

1 report, 1 independent Updated Thu 00:00
AI-generated briefing. Brind wrote this from the reports listed below and has updated it as the story developed. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Some supportReported by 1 outlet

Analyst reports compared Relay Therapeutics and I-Mab, two healthcare companies, across several financial metrics. Relay Therapeutics has a beta of 1.69, indicating higher volatility than the S&P 500, while I-Mab has a beta of 1.5. Analysts believe I-Mab is more favorable due to its higher probable upside, though Relay Therapeutics is currently trading at a lower price-to-earnings ratio.

From themarketsdaily.com

Why it matters

Some supportBrind's analysis of the reports

The comparison contrasts key investment factors, including institutional ownership, profitability, and valuation, which influences market perception of both companies. The findings highlight differences in risk profiles and potential returns between the two firms.

From themarketsdaily.com

Who's involved

  • Relay TherapeuticsHealthcare company whose market performance is being analyzed against I-Mab

Keep exploring

The entities involved

Coverage

Newest first; wire copies grouped